Document:

<PAGE>

                                                                   EXHIBIT 10.30

              CONFIDENTIAL PORTIONS HAVE BEEN OMITTED BASED UPON A
           REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2
              OF THE SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN
                      SEPARATELY FILED WITH THE COMMISSION

                           REGULATORY TRANSITION AND
                           -------------------------
                       SHORT-TERM DISTRIBUTION AGREEMENT
                       ---------------------------------

This Regulatory Transition and Short-term Distribution Agreement (hereinafter
referred to as this "Agreement") is entered into this First (1st) Day of April,
2002 by and between Century Medical, Inc. and its affiliates and subsidiaries
("CMI") and Micro Therapeutics, Inc. and its affiliates and subsidiaries
("MTI"). CMI and MTI hereby agree as follows:

     Article 1: The terms "Import License(s)," "Import Approval(s)," "Foreign
     ---------
Manufacturing Approval(s)," and "In-Country Caretaker" as used in this Agreement
shall have the same meanings, respectively, as the Japanese terms Yunyu Hinmoku
Tsuika Kyoka, Yunyu Shonin, Gaikoku Seizo Shonin, and Kokunai Kanrinin, as such
terms are defined and used in the Pharmaceutical Affairs Law of Japan and the
Enforcement Regulations thereof. The term "Product(s)" shall mean and include
any product(s) manufactured by MTI for which Import Approvals are held by CMI as
of March 31, 2002. The term "Earlier Distribution Agreement" shall mean that
certain Distribution Agreement dated September 23, 1998 by and between CMI and
MTI, as amended by that certain First Amendment to Distribution Agreement, dated
February 14, 2001.

     Article 2: This Agreement shall be effective from April 1, 2002 and shall
     ---------
remain in effect for a period of one (1) year, until March 31, 2003 (the "Term"
of this Agreement) on which date this Agreement shall expire automatically;
provided however that: (i) Articles 4, 9, and 10 hereof shall survive such
expiration for periods of fourteen (14), forty-four (44), and thirty (30) days,
respectively, and (ii) Sections 5.10, 9, 10, 12, 13 and 14 of the Earlier
Distribution Agreement, which have been incorporated herein pursuant to
Paragraph 1 of Exhibit B, shall survive such expiration.

     Article 3: During the Term of this Agreement CMI shall: (i) maintain (and
     ---------
update as necessary) Import Licenses for all of the Products; (ii) maintain an
Import Approval for each of the Products, until such time as MTI has obtained a
Foreign Manufacturing Approval for such Product; (iii) purchase the Products
from MTI at the prices listed on Exhibit A attached hereto; (iv) import and
distribute the Products in Japan in accordance with the terms and conditions set
forth on Exhibit B attached hereto; and (v) exercise reasonable efforts to sell
at least the same quantity of each of the Products as CMI sold during the one
(1) year period immediately preceding the Term of this Agreement.

     Article 4: During the Term of this Agreement CMI shall also cooperate with
     ---------
MTI and provide such information and assistance as MTI reasonably requires in
order to ensure that Japanese customers and their purchases of the Products are
not adversely affected by the expiration of this Agreement. Such cooperation and
assistance shall include (without limitation) those items set forth on Exhibit C
attached hereto.

     Article 5: During the Term of this Agreement CMI shall not import,
     ---------                                              ---
distribute or otherwise provide to any party in Japan any product which is
directly competitive with any of the Products. However nothing in this Agreement
shall prevent CMI from selling any competing product following the Term of this
Agreement or from engaging in any activity (whether during the Term of this
Agreement or otherwise) preparatory to the sale

<PAGE>

of such a product, including but not limited to the importation of such a
product for purposes of evaluation and regulatory review and approval.

     Article 6: Upon execution of this Agreement, CMI shall have no
     ---------
responsibility for clinical or regulatory development of any product
manufactured by MTI. CMI shall, however, cooperate with MTI and provide such
assistance as MTI reasonably requires in order to continue any clinical or
regulatory development activities previously undertaken or initiated by CMI for
such products and/or to derive value from such previous activities. Such
cooperation and assistance shall include (without limitation) delivery by CMI to
MTI of complete copies of all of the documents listed and described on Exhibit D
attached hereto, and reasonably adequate explanations of the contents of such
documents.

     Article 7: As soon as possible following the execution of this Agreement,
     ---------
MTI shall endeavor to obtain Foreign Manufacturing Approvals for all of the
Products. CMI shall provide such cooperation and assistance as MTI reasonably
requires for such purpose. Such cooperation and assistance shall include
(without limitation) the delivery by CMI to MTI of complete copies of all of the
documents listed and described on Exhibit E attached hereto.

     Article 8: MTI may appoint CMI as an importer and/or the In-country
     ---------
Caretaker of any or all of the Products for which MTI submits applications for
Foreign Manufacturing Approval during the Term of this Agreement; CMI shall
promptly accept such appointment(s) and each party shall promptly execute such
document(s) as are necessary for purposes of such application(s). Such
appointment shall be for a period not to exceed the Term of this Agreement.

     Article 9: Within fourteen (14) days following the Term of this Agreement,
     ---------
CMI shall deliver to MTI or its designee all of the Products in CMI's
possession. Such delivery shall be made at CMI's warehouse at 6-1-1 Heiwajima,
Ohta-ku, Tokyo 143-0006; and within thirty (30) days following the receipt of
all such Products from CMI, MTI or its designee shall pay to CMI (as payment in
full for all such Products) an amount equal to the lesser of: (i) one hundred
five percent (105%) of CMI's U.S. Dollar purchasing cost for such Products or
(ii) One Hundred Fifty Thousand U.S. Dollars ($150,000). For the purposes of
this Article 9, CMI's U.S. Dollar purchasing cost for each Product shall be the
price of such Product listed in Exhibit A herein.

     Article 10: In addition to the repurchase of inventory in accordance with
     ----------
Article 9 hereof, MTI shall pay to CMI, as a termination fee, a maximum total
amount of One Million Five Hundred Thousand U.S. Dollars (US$1,500,000), which
shall be payable in installments (each a "Milestone Payment") conditional upon
the achievement during the Term of this Agreement of certain transitional
objectives (each a "Milestone") listed and described on Exhibit F attached
hereto. MTI shall make each Milestone Payment within thirty (30) days following
the date on which the corresponding Milestone was achieved during the Term of
this Agreement. All payments by MTI in accordance with Articles 9 and 10 hereof
shall be non-refundable and payable without any set off or deduction for any
taxes or withholding.

     Article 11: All payments by MTI to CMI in accordance with Articles 9 and 10
     ----------
above shall be made by wire transfer to the following account:

            Name of Bank:    Sumitomo Mitsui Banking Corporation
            Name of Branch:  Shibuya Ekimae Branch
            Account No:      0232811
            Address:         1-2-2 Dohgenzaka, Shibuya-ku, Tokyo 150-0043

<PAGE>

     Article 12: Neither MTI nor its affiliates shall hire or solicit to hire
     ----------
any employee of CMI or its affiliates during the term of this Agreement and for
a period of five (5) years after the expiration or termination of this Agreement
without the prior written consent of CMI. Likewise neither CMI nor its
affiliates shall hire or solicit to hire any employee of MTI or its affiliates
during the term of this Agreement and for a period of five (5) years after the
expiration or termination of this Agreement without the prior written consent of
MTI.

     Article 13: The Earlier Distribution Agreement is hereby terminated on the
     ----------
date hereof (the "Termination Date") in its entirety and shall be of no further
force or effect; provided that, notwithstanding the foregoing, Sections 5.10, 9,
10, 12, 13, and 14 of the Earlier Distribution Agreement shall specifically
survive. This Agreement constitutes the entire understanding and agreement of
the parties hereto with respect to the subject matter hereof and supercedes and
replaces all prior agreements between CMI and MTI. Subject to the survival of
certain provisions of the Earlier Distribution Agreement as described above, all
such prior agreements and every provision thereof (including every provision
regarding the effects of termination of such agreements) are null and void and
of no force or effect, as if no such agreements had ever existed.

     Article 14: MTI hereby unconditionally and irrevocably releases, waives and
     ----------
relinquishes, and forever discharges both jointly and severally (i) CMI, (ii)
its affiliates and subsidiaries and (iii) their respective directors, officers,
employees, shareholders, subsidiaries, affiliates, attorneys, agents, advisors,
successors and assigns (collectively, the "CMI Released Persons") from any and
all claims, demands, actions, causes of action, damages, debts, liabilities,
obligations, costs and expenditures of any kind and nature whatsoever, whether
liquidated or contingent, known or unknown, suspected or unsuspected ("Claims"),
which MTI may now, or in the future, have or may have had the right to assert
against any of the CMI Released Persons arising out of or relating to the
Earlier Distribution Agreement or in connection with the termination thereof,
based on any matter, cause, fact or event that occurred or existed at any time
up to and including the Termination Date; provided that, the foregoing shall not
apply to any Claims that MTI may have for claims which specifically arise under
Section 14 (Indemnification and Limitation of Liability) of the Earlier
Distribution Agreement. For the purpose of implementing a full and complete
release and discharge of CMI, MTI expressly acknowledges that this Agreement is
intended to include, without limitation, all claims which MTI does not know or
suspect to exist in its favor against CMI at the time of execution hereof, and
that this Agreement expressly contemplates the extinguishment of all such
claims.

     Article 15: CMI hereby unconditionally and irrevocably releases, waives and
     ----------
relinquishes, and forever discharges both jointly and severally (i) MTI, (ii)
its affiliates and subsidiaries and (iii) their respective directors, officers,
employees, shareholders, subsidiaries, affiliates, attorneys, agents, advisors,
successors and assigns (collectively, the "MTI Released Persons") from any and
all claims, demands, actions, causes of action, damages, debts, liabilities,
obligations, costs and expenditures of any kind and nature whatsoever, whether
liquidated or contingent, known or unknown, suspected or unsuspected ("Claims"),
which CMI may now, or in the future, have or may have had the right to assert
against any of the MTI Released Persons arising out of or relating to the
Earlier Distribution Agreement or in connection with the termination thereof,
based on any matter, cause, fact or event that occurred or existed at any time
up to and including the Termination Date; provided that, the foregoing shall not
apply to any Claims that CMI may have which specifically arise under Section 9
(Product Liability), Section 10

<PAGE>

(Warranty) or Section 14 (Indemnification and Limitation of Liability) of the
Earlier Distribution Agreement. For the purpose of implementing a full and
complete release and discharge of MTI, CMI expressly acknowledges that this
Agreement is intended to include, without limitation, all claims which CMI does
not know or suspect to exist in its favor against MTI at the time of execution
hereof, and that this Agreement expressly contemplates the extinguishment of all
such claims

     In witness whereof, the parties hereto have caused this Agreement to be
duly executed on the day and year first above written.

For:  Micro Therapeutics, Inc. ("MTI")      For:  Century Medical, Inc. ("CMI")

      /s/ John B. Rush                            /s/ Yasuo Kyotani
      ---------------------------                 ---------------------------
By:   John Rush                             By:   Yasuo Kyotani
      President & Chief Executive Officer         President & CEO
      Hereunto Duly Authorized                    Hereunto Duly Authorized

<PAGE>

                                    Exhibit A
                                Purchasing Prices

                                                                Price Charged to
Product                                                            CMI by MTI
-------                                                         ----------------
Flow Rider                                                           $[*]
Flow Rider Plus                                                      $[*]
Equinox Balloon Systems                                              $[*]
MTI Hydrophilic Guidewires (Neuro)                                   $[*]
MTI Hydrophilic Guidewires (Peripheral)                              $[*]
Rebar 14 Microcatheters (Neuro)                                      $[*]
Rebar 18 Microcatheters #105-5085-143 (Neuro)                        $[*]
Rebar 18 Microcatheters (Peripheral)                                 $[*]
Rebar 027 Microcatheters (Peripheral)                                $[*]
Craig McNamara Infusion Catheters - 4F                               $[*]
Craig McNamara Infusion Catheters - 5F                               $[*]
Craig McNamara Infusion Catheters - 5F, Long                         $[*]
MicroMewi Infusion Catheters                                         $[*]
Mewi-5 Infusion Catheters                                            $[*]
Infusion Wires - Prostream                                           $[*]
Dual Check Valve                                                     $[*]

* CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH COMMISSION.

<PAGE>

                                    Exhibit B
                              Terms and Conditions

      During the Term of this Agreement, MTI shall supply and CMI shall import
and distribute the Products in accordance with the terms and conditions set
forth in this Exhibit B.

1.    The terms and conditions set forth in this Exhibit B are understood to
      include the same terms and conditions which were set forth in Articles or
      Sections 2.2, 4.1 (a)-(e), 5.1, 5.2, 5.4, 5.5, 5.6, 5.8, 5.9, 5.10, 6, 7,
      8.2, 8.4, 8.6, 8.7, 8.8, 8.9, 9, 10, 11, 12, 13, 14 and 16 of the Earlier
      Distribution Agreement ; the text of the aforementioned articles and
      sections is incorporated herein by reference. Defined terms contained in
      such Articles and Sections shall have the meanings assigned to such terms
      as set forth in the Earlier Distribution Agreement.

2.    MTI hereby appoints CMI as a distributor and importer of the Products
      within Japan, and CMI hereby accepts such appointment. Under no
      circumstances shall CMI have authority to sell, distribute or re-export
      any Products outside Japan.

3.    All orders for Products by CMI and modifications to such orders are
      subject to acceptance by MTI; provided, however, that such acceptance
      shall not be unreasonably withheld; and provided further that MTI shall
      use its commercially reasonable efforts to accept or refuse any purchase
      order within five (5) business days following receipt from CMI. MTI shall
      use commercially reasonable efforts to fulfill all orders by CMI for the
      Products in Japan. If MTI believes that it will not be able to satisfy
      CMI's orders for the Products, it shall promptly notify CMI, specifying
      the reasons for the delay and its expected duration. MTI shall have the
      right to cancel any order placed by CMI or to refuse or delay the shipment
      thereof if CMI shall fail to meet any payments.

4.    Each Product delivered to CMI will have upon shipment a minimum remaining
      shelf life of three-fourths (3/4) of such Product's approved shelf life.
      MTI reserves the right to change the design or specifications of any of
      the Products or part thereof at any time and with ninety (90) days prior
      notice to CMI. MTI also reserves the right to discontinue the manufacture
      and distribution of any of the Products at any time with ninety (90) days
      prior notice to CMI and without substitution, in MTI's sole discretion.

5.    The non-defaulting Party may terminate this Agreement, immediately upon
      the giving of written notice to the defaulting Party, in the event that
      the defaulting Party defaults in the material performance of any
      obligation under this Agreement and fails to cure such default within
      sixty days after such written notice.

<PAGE>

                                    Exhibit C
                           Information and Assistance
                              To Be Provided by CMI
                          In Accordance With Article 4

1.   For the calendar quarter ending March 31, 2002, and for each subsequent
     calendar quarter up to and including the quarter ending March 31, 2003, CMI
     shall deliver to MTI a sales report which (for each of the Products) shall
     list the quantity sold by CMI, CMI's average selling price to each buyer
     and in total, and the number of end-users. CMI shall deliver each such
     report to MTI by fax or email no later fourteen (14) days following the end
     of each quarter. The final two (2) such reports (i.e. for the quarters
     ending December 31, 2002 and March 31, 2003) shall identify each
     sub-distributor and end-user distinctly, individually and by its proper
     name.

2.   CMI shall provide to MTI, by no later than January 31, 2003, a list
     identifying by name, address, and telephone number, all of CMI's
     sub-distributors and end-users who have purchased Products during the nine
     (9) month period ending December 31, 2002. This list shall also include the
     names of the key personnel and key contact doctor(s) at each end-user, and
     contact information therefor, to ensure that MTI has the information
     necessary to enable it to visit and follow up with each such end-user.

3.   CMI shall jointly with MTI or its designee, draft, sign, and send, by
     January 31, 2003, a letter to each such sub-distributor and end-user,
     informing them of how the Products will be distributed as of April 1, 2003.

4.   Within fourteen (14) days following September 30, 2002, CMI shall provide
     to MTI an inventory report itemizing all of the Products in CMI's inventory
     as of September 30, 2002.

<PAGE>
                                    Exhibit D
                                List of Documents
                             To Be Delivered by CMI
                          In Accordance With Article 6

1.   Information Related to [*]:
     --------------------------

     a.   CMI's letter/fax (1-page + 2-pages attachments) dated Sept. 2, 1999 to
          the officer of "Pharmaceuticals and Medical Devices Evaluation Center"
          ("PMDEC") advising that classification of [*] is confirmed by MHLW
          through the officer of Tokyo Metropolitan government office.

     b.   Draft (10-pages) of the "Clinical Investigation Plan" ("CIP") to MHLW
          as of HEISEI-11 (Aug 1999) plus all attachments thereto (2-binders
          including several bio-compatible test data, draft of clinical protocol
          and cases report forms).

     c.   Draft of the 2-pages test results dated Oct 25, 1999 (Heisei-11) of
          [*] plus all original data and report(s) from outside laboratories.

     d.   Memoranda of all relevant meetings with [*].

2.   Information Related to [*]:
     --------------------------

     a.   Documentation with MHLW regarding why this product cannot be approved
          as me-too, but must be either New or Improved.

     b.   All data, reports, published articles, and other information received
          from MTI, and any Japanese translations of such material.

     c.   Data, other results, and reports of any testing performed in Japan.

* CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH COMMISSION.

<PAGE>

                                    Exhibit E
                                List of Documents
                             To Be Delivered by CMI
                          In Accordance With Article 7

For all of the Products, CMI shall deliver to MTI:

1.   Up to date copies of the Import Approval documents, including any Partial
     Change Amendments (Ichibu Henko Shinsei, "PCA"), if any, for such Products,
     along with all attached test data and, for each Import Approval, a signed
     letter stating that the data and information specified in the Items of
     Article 21-6, Paragraph 1, of the Japanese Enforcement Regulations are
     transferred to MTI for all Import Approvals (except for Rebar Micro
     Catheter). The aforesaid Import Approvals shall include the Import
     Approvals listed hereunder:

     Import Approval                                 Shonin Number
     ------------------------------------------------------------------
     a.  Flow Rider Micro Catheters                       [*]
     b.  Flow Rider Plus Micro Catheters                  [*]
     c.  Equinox Balloons                                 [*]
     d.  Hydrophilic Guidewires                           [*]
     e.  Rebar Micro Catheter                             [*]
     f.  Infusion Catheters - Craig McNamara              [*]
     g.  Infusion Catheters - MicroMewi                   [*]
     h.  Infusion Catheters - Mewi-5                      [*]
     i.  Infusion Wires - Prostream                       [*]

2.   Copies of any and all communications with the Japanese regulatory
     authorities related to the review(s) currently ongoing of any PCA
     applications, including the PCA to the Rebar Micro Catheter Import
     Approval.

3.   Evidence of Approval of the Application(s) (currently under review by the
     MHLW) for PCAs, including the PCA Application for Rebar Micro Catheter. 4.
     A letter such as that described in 1. hereinabove for Rebar Micro Catheter.

* CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH COMMISSION.

<PAGE>

                                    Exhibit F
                        Milestones and Milestone Payments

<TABLE>
<CAPTION>
                                     Milestone
------------------------------------------------------------------------------    Milestone
No.                             Title/Description                                  Payment
---   ------------------------------------------------------------------------    ---------
<C>   <S>                                                                         <C>
1.    Signature                                                                     $[*]

      This milestone will have been achieved when MTI and CMI have both
      signed this Agreement.

2.    Copies of Shonin (except for [*])                                             $[*]

      This milestone will have been achieved when CMI has delivered to MTI
      all of the documents listed on Exhibit E, except for those items marked
      with an asterisk ("*"), and reasonably adequate explanations thereof.

3.    Applications for Foreign Manufacturing Approval                               $[*]

      This milestone will have been achieved when MTI (having received from
      CMI such assistance as was reasonably necessary for such purpose,
      including achievement of Milestone #2 hereinabove) has submitted (which
      submissions shall not be unreasonably delayed by MTI) to the proper
      authorities its applications for Foreign Manufacturing Approvals for
      all of the Products except [*].

4.    Rebar with [*] Application for FMA                                            $[*]

      This milestone will have been achieved when MTI (having received from
      CMI such assistance as was reasonably necessary for such purpose,
      including all of the documents listed with an asterisk ("*") on Exhibit
      E and reasonably adequate explanations thereof) has submitted (which
      submission shall not be unreasonably delayed by MTI) to the proper
      authorities its application for Foreign Manufacturing Approval for [*].

5.    Receipt of Other Clinical & Regulatory Information                            $[*]

      This milestone will have been achieved when MTI has received from CMI
      all of the documents listed on Exhibit D, reasonably adequate
      explanations thereof, and such other assistance as MTI reasonably
      requires in order to continue clinical and regulatory development
      activities previously undertaken or initiated by CMI for the Products.
</TABLE>

* CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH COMMISSION.

<PAGE>

                                    Exhibit F
                  Milestones and Milestone Payments (continued)

<TABLE>
<CAPTION>
                                     Milestone
------------------------------------------------------------------------------    Milestone
No.                             Title/Description                                  Payment
---   ------------------------------------------------------------------------    ---------
<C>   <S>                                                                         <C>
6.    Receipt of Foreign Manufacturing Approvals                                    $[*]

      This milestone will have been achieved when MTI (having received from
      CMI such assistance as was reasonably necessary for such purpose,
      including a copy at the appropriate time of the notification of the
      cancellation of the Import Approval for each Product), has obtained
      Foreign Manufacturing Approvals for all of the Products except [*].

7.    Receipt of  [*] FMA                                                           $[*]

      This milestone will have been achieved when MTI (having received from
      CMI such assistance as was reasonably necessary for such purpose,
      including a copy at the appropriate time of the notification of the
      cancellation of the Import Approval for such Product), has obtained
      Foreign Manufacturing Approval for [*].

8.    Receipt of Sales Reports and Customer Lists                                   $[*]

      This milestone will have been achieved when all of the items set forth
      in Exhibit C have been completed.

9.    Achievement of Sales Target                                                   $[*]

      This milestone will have been achieved on March 31, 2003, if: (a) CMI
      has exercised reasonable efforts to grow sales in accordance with
      Article 3, Item (v) or (b) CMI's sales during the Term of this
      Agreement are at least [*]% of the amount it sold during the one (1)
      year period immediately preceding the Term of this Agreement.

10.   Successful Completion of This Agreement                                       $[*]

      This milestone will have been achieved on March 31, 2003, unless MTI
      demonstrates in writing to CMI on or before April 10, 2003, that,
      during the Term of this Agreement, CMI has intentionally and
      substantially failed to satisfy its material obligations under this
      Agreement.
</TABLE>

* CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH COMMISSION.<PAGE>

                                                                    EXIBIT 10.31

                      Lease and Support Services Agreement

     THIS AGREEMENT is made as of April 18, 2002 ("Effective Date"), by and
between Micro Therapeutics, Incorporated, a Delaware corporation with its
principal place of business at 2 Goodyear, Irvine California ("MTI") and ev3
International, Inc., a Delaware corporation with its principal place of business
at 1861 Buerkle Road, White Bear Lake, Minnesota ("ev3").

     WHEREAS, MTI develops, manufactures and markets minimally invasive devices
for the treatment of neurovascular and peripheral vascular diseases;

     WHEREAS, MTI has space in its Irvine California headquarters which it is
willing to make available to ev3 in exchange for reasonable rent;

     WHEREAS, MTI is also willing to make available to ev3 certain support
services in order to minimize the number of employees ev3 would need to hire at
the Irvine location;

     WHEREAS, ev3 is interested in leasing space from MTI and in paying MTI for
support services in order to enhance the efficiencies in its business
relationship with MTI, and to have a California base of operations.

     NOW, THEREFORE, the parties hereto agree as follows:

     1.   Term. The term of this lease shall be for 3 (three) years, beginning
          ----
          April 1, 2002, and renewable by ev3 for another 2 (two) year term upon
          written notice to MTI at least 6 months prior to the end of the
          initial term.

     2.   Premises. MTI shall lease the office space to ev3 as described and
          --------
          diagramed on Exhibit A (the "Premises"). The Premises shall include
          two enclosed offices, and a reception area large enough for a
          secretary's desk, as well as a private entrance with exterior space
          for appropriate signage identifying ev3. The rent for the Premises
          shall include heat, air conditioning, water and sewer, electricity ,
          insurance (solely as it relates to the Premises), and adequate parking
          spaces.

     3.   Support Services. During the term of this lease, MTI shall provide
          ----------------
          reasonable support for the usage of the Premises, including janitorial
          service, maintenance and repair, security, Information Technologies
          support, phone system support, mailroom support, and other typical
          office support services incurred in the day-to-day operation of a
          medical device

<PAGE>

          business as the parties may agree upon from time to time ("Services").
          Such support does not include access by ev3 to any of MTI's
          confidential or proprietary information.

     4.   Payment for Rent and Services. ev3 shall pay to MTI an aggregate
          -----------------------------
          monthly amount in consideration of the use of the Premises and the
          provision of the Services, as set out on Exhibit B (the "Fees"). The
          Fees cover all the items listed in Sections 2 and 3 above, and shall
          be payable monthly on the 10th day of each month. Those services
          provided by MTI which fall outside the agreed upon scope of Services
          under this Agreement, if any, shall carry additional charges to ev3,
          which charges shall be payable within 30 days of receipt of the
          invoice from MTI for such additional services. Any additional services
          shall be provided by MTI on a cost plus 5% basis.

     5.   Expenses. In the event that ev3 employees travel to MTI's facility
          --------
          primarily on MTI business, rather than primarily on ev3 business,
          those travel expenses shall be submitted by such employee(s) to MTI
          for reimbursement, and MTI agrees to reimburse such employee(s) as
          promptly as it reimburses its own employees.

     6.   Use. ev3 agrees to use the Premises in accordance with the provisions
          ---
          of that certain Industrial Real Estate Lease (the "Master Lease"), by
          and between MTI and New Goodyear, LTD., a California Limited
          Partnership ("Landlord"), dated as of June 10, 1998, and for no other
          use or purpose.

     7.   Insurance and Indemnification. MTI shall carry sufficient liability,
          -----------------------------
          fire and disaster insurance to cover the building (both interior and
          exterior) and to cover any claims which may be brought against ev3 or
          MTI for damages incurred related to the building or the activities and
          business conducted in the building. MTI shall name ev3 as an
          additional insured on it policies. ev3 hereby agrees to protect,
          defend, indemnify and hold MTI harmless from and against any and all
          liabilities, claims, expenses, losses and damages, including, without
          limitation, reasonable attorneys' fees, costs and disbursements, that
          may at any time be asserted against MTI by any person as a result of
          ev3's use and/or occupancy of the Premises. MTI hereby agrees to
          protect, defend, indemnify and hold ev3 harmless from and against any
          and all liabilities, claims, expenses, losses and damages, including,
          without limitation, reasonable attorneys' fees, costs and
          disbursements, that may at any time be asserted against ev3 by any
          person as a result of MTI's use and/or occupancy of

<PAGE>

          its premises covered under the Master Lease. The provisions of this
          Section 7 shall survive the expiration or earlier termination of the
          Master Lease and/or this Agreement.

     8.   Termination. This Agreement may be terminated by either party upon 60
          -----------
          days notice for the material breach of the terms of this Agreement by
          the other, provided, however, that the party electing to terminate has
          provided written notice of such material breach to the other party and
          has given the other party 30 days to cure such breach. Additionally,
          this Agreement shall automatically terminate upon termination of that
          certain Sales Representative Agreement between the parties, dated as
          of November 16, 2001.

     9.   Damage to the Premises. In the event the Premises becomes unusable due
          ----------------------
          to fire, contamination, governmental taking, or for any other reason,
          ev3 shall be relieved from the obligation to make payment of the Fees
          due hereunder for the duration that the Premises is unusable for ev3
          business. If the Premises remains unusable for a period greater than
          60 days, ev3 at its option may elect to terminate this Agreement with
          no further obligation. If the Premises remains unusable for a period
          greater than 120 days, MTI shall also have the right to terminate this
          Agreement with no further obligation.

     10.  Notices. Any notice required or permitted under this Agreement shall
          -------
          be in writing and either mailed by nationally recognized overnight
          courier, registered or certified mail, return receipt requested, or by
          express delivery service to the other party. All notices shall be sent
          to the address set forth in the first paragraph of this Agreement or
          at such other addresses or to such other persons as such party may
          previously have designated by written notice. Notice will be deemed to
          have been given upon receipt.

     11.  Severability. If any provision of this Agreement is held to be
          ------------
          unenforceable, in whole or in part, such holding will not affect the
          validity of the other provisions.

     12.  Governing Law. This Agreement will be governed by and interpreted in
          -------------
          accordance with the laws of the State of California.

     13.  Entire Agreement. This Agreement and its Exhibits constitute the
          ----------------
          complete and entire statement of all terms, conditions and
          representations of the agreement between MTI and ev3 with

<PAGE>

          respect to its subject matter and supersedes all prior writings or
          understandings regarding this subject matter. This Agreement does not
          affect or alter the terms of the Sales Representative Agreement
          between the parties dated November 16, 2001.

     IN WITNESS WHEREOF, MTI and ev3 cause this Agreement to be executed by
their duly authorized representatives identified below.

Micro Therapeutics, Inc.                   ev3 International, Inc.
("MTI")                                    ("ev3")

By:    /s/ John B. Rush                    By:    /s/ Jerry Johnson
       --------------------------------           ------------------------------

Name:  John B. Rush                        Name:  Jerry Johnson
       --------------------------------           ------------------------------

Title: President and CEO                   Title: CFO
       --------------------------------           ------------------------------

<PAGE>

                                    Exhibit A

                                    Premises

The area outlined in the lower left-hand corner of the diagram below constitutes
the Premises.

                   [Graphic depicting diagram of office space]

<PAGE>

                                    Exhibit B

                                      Fees

Annually, the monthly Fee shall be calculated and agreed upon by the parties to
this Agreement, and shall be the result of (a) the sum of annual costs related
to items appearing in MTI's Annual Operating Plan from Departments 096 and 097
that comprise the Rent and Services as described in paragraphs 2 and 3 of this
Agreement, divided by (b) the square footage of the entire building space
occupied by MTI, multiplied by (c) the square footage of the Premises, divided
by (d) 12, which is expressed mathematically as: (((a) / (b)) x (c)) / (d).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}]]